Comparison of P-32-postlabeling and HPLC-FD analysis of DNA adducts in rats acutely exposed to benzo(a)pyrene

被引:21
作者
Godschalk, RWL
Vermeer, ITM
Kriek, E
Floot, B
Schilderman, PAEL
Moonen, EJC
Kleinjans, JCS
vanSchooten, FJ
机构
[1] MAASTRICHT UNIV,DEPT HLTH RISK ANAL & TOXICOL,NL-6200 MD MAASTRICHT,NETHERLANDS
[2] NETHERLANDS CANC INST,DIV MOL CARCINOGENESIS,NL-1066 CX AMSTERDAM,NETHERLANDS
关键词
DNA adducts; polycyclic aromatic hydrocarbons; HPLC; P-32-postlabeling;
D O I
10.1016/S0009-2797(97)03765-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
DNA adduct analysis is often used for biomonitoring individuals exposed to polycyclic aromatic hydrocarbons (PAH). The P-32-postlabeling assay is routinely applied to study the formation of aromatic bulky adducts, but cannot positively identify individual adduct types. Recently, an HPLC assay with fluorescence detection (HPLC-FD) was developed which was sufficiently sensitive to detect adducts formed by benzo[a]pyrene (B[a]P) diolepoxide isomers [(+/-)anti- and(+/-)syn-BPDE] in occupationally exposed subjects (Rojas et al. Carcinogenesis, 16 (1995) 1373-1376). In this study, we compared both techniques using DNA samples of rats which were treated i.p. with B[a]P (10 mg/kg bw). The internal dose was assessed by measuring 3-OH-B[a]P excretion in urine. The detection limit of the HPLC-FD assay varied from 0.5 to 7.4 adducts per 10(8) nucleotides, while the detection limit of the P-32-postlabeling assay was around 1 adduct per 10(9) nucleotides. HPLC-FD analysis showed that BPDE-DNA adduct levels were highest in the heart, lung and liver respectively. The most predominant B[a]P-tetrol was the I-1 isomer, which derives from hydrolysis of the major reaction product of DNA and (+)-anti-BPDE. P-32-postlabeling analysis revealed an adduct spot that comigrated with a [H-3]BPDE-DNA standard. The putative BPDE-DNA adduct levels were highest in heart followed by lung and liver and correlated significantly with tetrol I-1 levels determined by HPLC-FD (r = 0.72, P = 0.006). In samples in which both tetrol I-1 and II-2 were detected by means of HPLC-FD, this correlation was even better (r = 0.95, P = 0.01). Estimated half-lives of BPDE-DNA adducts were in the ranking order; heart, lung and liver for both techniques. By P-32-postlabeling, adducts other than BPDE-DNA were also found, resulting in highest total DNA adduct levels in the liver, heart and lung respectively. Furthermore, mean 24 h urinary excretion of 3-OH-B[a]P was related to BPDE-DNA adduct levels in lung, liver and heart. The P-32-postlabeling assay is sensitive and capable of detecting exposures to complex mixtures, whereas the HPLC-FD assay can be used to identify BPDE-isomers and might therefore be of value in risk assessment of individuals exposed to PAH. (C) 1997 Elsevier Science Ireland Ltd.
引用
收藏
页码:41 / 54
页数:14
相关论文
共 24 条
[1]   Evidence of anti-benzo[a]pyrene diolepoxide-DNA adduct formation in human colon mucosa [J].
Alexandrov, K ;
Rojas, M ;
Kadlubar, FF ;
Lang, NP ;
Bartsch, H .
CARCINOGENESIS, 1996, 17 (09) :2081-2083
[2]  
ALEXANDROV K, 1992, CANCER RES, V52, P6248
[3]  
[Anonymous], 1993, MOL EPIDEMIOLOGY PRI
[4]   Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53 [J].
Denissenko, MF ;
Pao, A ;
Tang, MS ;
Pfeifer, GP .
SCIENCE, 1996, 274 (5286) :430-432
[5]   DIFFERENCES IN DETECTION OF DNA ADDUCTS IN THE P-32-POSTLABELING ASSAY AFTER EITHER 1-BUTANOL EXTRACTION OR NUCLEASE P1-TREATMENT [J].
GALLAGHER, JE ;
JACKSON, MA ;
GEORGE, MH ;
LEWTAS, J ;
ROBERTSON, IGC .
CANCER LETTERS, 1989, 45 (01) :7-12
[6]  
HALL M, 1990, CHEM CARCINOGENESIS, V1, P327
[7]   DNA-ADDUCTS, MUTATIONS AND CANCER [J].
HEMMINKI, K .
CARCINOGENESIS, 1993, 14 (10) :2007-2012
[8]  
IZOTTI A, 1995, CANCER EPIDEM BIOMAR, V4, P105
[9]   BIOLOGICAL MONITORING OF POLYCYCLIC AROMATIC-HYDROCARBONS - METABOLITES IN URINE [J].
JONGENEELEN, FJ ;
BOS, RP ;
ANZION, RBM ;
THEUWS, JLG ;
HENDERSON, PT .
SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH, 1986, 12 (02) :137-143
[10]   BIOMARKERS FOR INDIVIDUAL SUSCEPTIBILITY TO CARCINOGENIC AGENTS - EXCRETION AND CARCINOGENIC RISK OF BENZO[A]PYRENE METABOLITES [J].
LIKHACHEV, AJ ;
BENIASHVILI, DS ;
BYKOV, VJ ;
DIKUN, PP ;
TYNDYK, ML ;
SAVOCHKINA, IV ;
YERMILOV, VB ;
ZABEZHINSKI, MA .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1992, 98 :211-214